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cells, and total lymphocyte counts along with platelet
counts e account for the majority of variability in IR in this
cohort. CD4-CD8- T cells and NKT cells may be emerging
biomarkers of chronic GVHD activity. Lymphocyte activation
without overt GVHD adds to the complexity of the study of
post-HCT IR. Withmore patient data, predictive classiﬁcation
of GVHD status by peripheral blood cell subset testing may
become possible.Table
Factor and Discriminant Analysis
Factor Percent
of Data
Variance
Cumulative
Percent
of Variance
Cumulative
Percent
Misclassiﬁed
on DA
Cumulative
P
Factor 1 (CD4+,
CD8+, CD45RO- T
cells subsets)
33.91 33.91 41.9 0.54
Factor 2 (naïve B
and switched
memory B cell
subsets)
28.19 62.10 35.0 0.10
Factor 3 (ALC +
platelet count)
25.54 87.65 13.3 0.06367
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Background: Allogeneic hematopoietic cell transplantation
(HCT) can be curative in patients with acute myeloid
leukemia (AML), but relapse after HCT continues to be
a leading cause of mortality. Treatment options for these
patients are limited. Hypomethylating (HM) agents such as
5-azacytidine and 5-aza-2'-deoxycytidine (gemcitabine)
have immunomodulatory properties including augmenting
tumor antigen presentation that may enhance graft-versus-
leukemia (GVL) effect. Moreover, inhibitory effects of these
agents on T-cell activation and cytokine production may lead
to low incidence of graft-versus-host-disease (GVHD). Our
aim was to describe the outcomes, including response,
survival, and incidence of GVHD, in patients treated with HM
agents for relapsed AML or loss of donor chimerism (LDC)
after HCT.
Methods: Subjects were patients with relapsed AML or LDC
after allogeneic HCT for AML or high-risk myelodysplastic
syndrome (MDS) whowere treatedwith either 5-azacytidine
or decitabine at the University of Pittsburgh Cancer Institute.
Relapse was deﬁned as a period of complete remission (CR)
after HCT followed by re-occurrence of>5%myeloid blasts or
cytogenetic abnormalities on bone marrow biopsy. LDC was
deﬁned as <100% donor chimerism without relapse. Retro-
spective analysis was performed to determine response to
HM agents, overall survival from time of relapse or LDC, and
incidence of GVHD.
Results: Thirteen patients were identiﬁed, whose median
age was 57 years (22-62), and median time to relapse after
HCT was 124 days (30 to 847). Seven patients receivedmyeloablative conditioning regimens, and 6 patients
received reduced-intensity conditioning. Nine patients had
relapsed AML, and 4 patients had LDC. Ten patients were
treated with decitabine and 3 patients were treated with 5-
azacytidine, with median cycles received of 4 (1-9). After
hypomethylating agents, 9 of 12 (75%) evaluable patients had
a CR, and 3 patients had progressive disease. Eight of 10 (80%)
evaluable bone marrow biopsies revealed 100% donor
chimerism after treatment with a HM agent. Grade I-IV acute
GVHD of the liver occurred in 6 patients, 3 of whom had
isolated liver involvement. Median survival was 308 days
(44-857) from time of relapse or LDC, and 7 patients are alive
at time of analysis and remain in CR.
Conclusions: HM agents in patients with relapsed AML can
be effective in reversing loss of donor chimerism and
inducing CR. This may be due to epigenetic changes and
subsequent immunomodulatory effects that enhance GVL
effect. There may be a relationship between use of these
agents with development of acute liver GVHD, and further
exploration into pathophysiology and predisposing factors
are warranted. The use of HM agents as a maintenance
strategy in patients at high risk of relapse after HCT should be
further explored.368
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Background: The Hematopoietic Cell Transplantation
Comorbidity Index (HCT-CI) is predictive of non-relapse
mortality (NRM) and overall survival (OS) after allogeneic
stem cell transplant (SCT). However, the HCT-CI has been less
well validated in the older SCT patient population. We
hypothesized that the HCT-CI could have less discriminative
ability in this population, where multiple comorbidities are
common.
Methods: We performed a retrospective study of patients
50 years of age who underwent SCT at UCSF, where HCT-CI
was recorded prospectively as part of routine clinical care
starting in 2007. Outcomes measured included NRM and OS,
as well as grade 3-4 non-hematologic adverse events to 100
days post-SCT, duration of hospital stay, and risk of re-
hospitalization with the ﬁrst 100 days. Kaplan Meier
methods with log-rank tests were used for analysis of NRM
and OS; Student's t test or chi-square test were used for the
remaining outcome measures.
Results: We identiﬁed 59 patients 50 years of age with
complete HCT-CI data. The median age was 60 years (range
50-74) and 31 (53%) of the patients were male. Most SCTs
were for AML (n¼30, 51%) orMDS (n¼9,15%). SCTswere non-
myeloablative in 24 patients (41%) and conditioning was
ﬂudarabine/busulfan-based in 53 patients (90%). Median
follow up was 22 months.
Twelve patients had HCT-CI score of 0 (20%), 19 had HCT-
CI score of 1-2 (32%) and 28 had HCT-CI score 3 (47%). High
HCT-CI score (3) was associated with signiﬁcantly
decreased OS (median OS not reached for HCT-CI 0-2 vs 14
months for HCT-CI 3; hazard ratio 2.2, P ¼ .02). This
remained signiﬁcant in multivariate analysis that included
age, KPS, treatment intensity, and the presence or absence of
Abstracts / Biol Blood Marrow Transplant 19 (2013) S279eS312S294GVHD as covariates (hazard ratio 2.2, P ¼ .03 for HCT-CI;
p¼NS for all other covariates). NRM was low in our patient
population (12%), and was not signiﬁcantly different
between HCT-CI groups. Grade 3-4 non-hematologic adverse
events within the ﬁrst 100 days after SCT were signiﬁcantly
more common in the higher HCT-CI groups (P ¼ .02). The
most common adverse events were infectious and gastro-
intestinal. Risk of re-hospitalization within the ﬁrst 100 days
after SCT was not statistically different between groups (17%,
37% and 36% for HCT-CI¼0, 1-2 and 3 respectively, P ¼ .45),
although patients with HCT-CI¼0 did have a trend toward
a lower risk than patients with HCT-CI>0 (17% vs 36%, P¼ .2).
There was no difference in the duration of SCT hospitaliza-
tion between HCT-CI groups.
Conclusion: Despite a high incidence of multiple comor-
bidities (HCT-CI score 3) in our older cohort, HCT-CI
retained its ability to predict OS, speciﬁcally by distinguish-
ing those with HCT-CI 3 as having a particularly poor
prognosis. HCT-CI score 3 was a better predictor of OS than
age or KPS. We conclude that HCT-CI remains a useful
predictor of outcomes in older patients undergoing alloge-
neic SCT.369
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Continuity of care (COC) is acknowledged as a core quality
measure in medicine. There is a little literature known about
the impact of COC on OS after allogeneic hematopoietic stem
cell transplantation Allo-HCT.
Method: Between July 2009 and May 2012, 74 consecutive
Allo-HCT were performed at our center. The patient's clinical
care for the ﬁrst consecutive 41 patients was shared between
the physicians independent of primary transplant physician
(Non- COC). We hypothesized that COC improve OS after
Allo-HCT and the subsequent 33 patients (COC) were fol-
lowed by their transplant physician both as in-patient and
outpatient. Physician's contribution into the care of each
individual patient was calculated from physicians billing
visits. Patient characteristics are shown in table I. Graft vs.
host disease (GVHD) prophylaxis was Calcineurin inhibitor
with MTX/Mycophenolate with the addition of Thymoglo-
bulin for MUD and mismatched RD.
Results: The average contribution of the primary transplant
physician into their patients care during the ﬁrst year post-
transplant was 49% vs. 80% for Non-COC and COC groups
respectively (P¼0.01). There was no difference in patient
characteristics between COC and Non-COC groups except for
older patients in Non-COC. With median duration of follow
up of 815 days for Non-COC and 320 days for COC groups, the
1- year OS was 56% vs. 75% respectively (P¼0.07). Similarly,
there was a trend toward improved DFS for COC (1-year DFS
of 68% vs. 48%, P¼0.11). Both cumulative incidence of relapse
and treatment related mortality (TRM) at 1-year were lower
in COC compared to Non-COC groups; 9% vs. 25% and 17% vs.
25% respectively. The cumulative incidence of grade II eIV
acute GVHD was 64% for Non-COC vs. 46% COC respectively.
There was more patients with grade III/IV aGVHD; 13/41
(32%) in Non-COC compared to 6/33(18%) in COC, however
this difference was not statistically signiﬁcant (p¼0.27).Additionally, there was no difference in OS in patients with
grade III/IV aGVHD in Non-COC (13 patients) vs. COC (6
patients), P¼0.85. In contrast, Patients without grade III/IV
aGVHD had a statistical OS advantage in favor of COC (27
patients) vs. Non-COC (28 patients) with one year OS of 90%
vs. 68% respectively, P¼0.05. Cumulative incidence of chronic
GVHD at one year was 77% for COC and 48% for Non-COC
patients, P¼0.02.
Conclusion: Continuity of care may favorably improve OS
after Allo-HCT. COC did not improve OS in patients with
severe aGVHD but may result in OS advantage in patients
with grade II aGVHD. Personnel knowledge of the patients
and promptness in initiating GVHD therapy in COC group
may have contributed to the improved OS in patients with
grade II aGVHD. Similarly, the more intense immune
suppression for patients with severe GVHD in NCOC
group may have contributed to higher relapse and TRM
observed.370
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With the growing diversity in race and ethnicity of the
American population, there is a need to characterize the
disparities in access and outcomes of hematopoietic cell
transplantation (HCT) for the racial and ethnic minorities.
This single center study examined the association of
ethnicity/ race with outcomes after HCT. Clinical information
of 301 adult patients who underwent single allogeneic HCT
for a hematological disorder at Mayo Clinic in Arizona from
11/03 to 06/12 was obtained from the institutional database
and retrospective chart review. Information about ethnicity
was self-reported by patients. Median follow-up was 20
months (range 3-106 months). Overall survival was
compared between the racial/ ethnic groups using Cox
regression while adjusting for other clinical factors.
The study included 224 white patients (75%) and 77
ethnic minority patients (25%). Non-whites/ Hispanics were
younger at HCT (median age 40 vs. 56, P ¼ .001). Use of
myeloablative conditioning (61% vs. 31%, P < .001) and
related donors (50% vs. 35%, P ¼ .01) was more common in
Non-whites/ Hispanics. There were no differences in disease
diagnosis and risk, gender distribution and HCT- comorbidity
index between the two groups. More Non-whites/Hispanics
were unemployed (51% vs. 25%; P < .001). No statistically
signiﬁcant differences in the incidence of post-transplant
complications including infections, veno-occlusive disease,
grade II-IV acute and NIH chronic GVHD were seen between
the two groups. Cumulative incidence of relapse at 5 years
was higher in Non-whites/ Hispanics (33% vs. 22%; P ¼ .03).
Though the univariate analysis showed no differences in
overall survival (5 year OS: 52% for Whites vs. 50% for Non-
whites/Hispanics; P ¼ .44), a higher risk for mortality was
seen in the multivariate analysis for ethnic minorities as
compared to the white patients. (Table)
